Clinical Trials
30 trialsTQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Beijing Friendship Hospital
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy
Peking Union Medical College Hospital
Escape
Sun Yat-sen University
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
Chinese PLA General Hospital
Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer
Sun Yat-sen University
Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer
Beijing Friendship Hospital
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
Peking Union Medical College Hospital
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
Beijing Friendship Hospital
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
Sun Yat-sen University
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
Sun Yat-sen University
LEADER-001
The First Hospital of Jilin University
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
Tongji Hospital
Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
Sixth Affiliated Hospital, Sun Yat-sen University
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
Third Affiliated Hospital, Sun Yat-Sen University
sPLENTY-pc
RenJi Hospital
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
REVO
Fujian Cancer Hospital
PLATIC
Sun Yat-sen University
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy
The First Hospital of Jilin University
AIPD-1
Sun Yat-sen University
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
Shanghai Changzheng Hospital
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Chinese PLA General Hospital
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Chinese PLA General Hospital
Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
Chinese PLA General Hospital